Moderna's mRNA Flu Vaccine Gets FDA Approval
On Wednesday, the FDA granted approval to Moderna for mFlusiva, an mRNA-based vaccine for seasonal influenza, making it the first of its kind to receive regulatory clearance globally. This approval is applicable to individuals aged 50 and above, marking the fourth product by Moderna to gain FDA endorsement. Initially, the FDA had opted not to review the vaccine, although the reasons for this decision were not revealed. This milestone highlights the advancements in mRNA technology, which rose to prominence during the COVID-19 crisis. The approval could enhance the use of mRNA in seasonal flu vaccinations, potentially leading to more effective and swiftly adaptable options compared to traditional egg-based vaccines. Quartz reported the announcement, though specific details on efficacy, distribution, or pricing were not provided.
Key facts
- Moderna received FDA approval for mFlusiva, an mRNA-based seasonal flu vaccine.
- The approval was granted on Wednesday.
- mFlusiva is the first mRNA flu vaccine to be approved by a regulatory body worldwide.
- The vaccine is approved for adults aged 50 years and older.
- mFlusiva is Moderna's fourth FDA-approved product.
- The FDA initially refused to review the vaccine before approving it.
- Moderna's stock ticker is $MRNA.
- The source is Quartz, with URL https://qz.com/moderna-mrna-flu-vaccine-mflusiva-fda-approval-080626.
Entities
Institutions
- Moderna
- FDA
Sources
- Quartz —